A Swiss femtech company called KOVE Medical has raised CHF 1.6 million in seed funding and is now preparing for its first clinical trial in humans, according to a report by Startupticker.
The funding round positions KOVE Medical to move from early-stage development into a First in Human study, a critical milestone in the regulatory pathway for any new medical device. First in Human studies are the initial phase of human testing, designed to assess safety before a device can be evaluated more broadly in larger patient populations.
KOVE Medical is focused on women's health, operating in the femtech sector, which covers technology and medical products designed specifically to address female physiology and health conditions. The femtech industry has grown significantly in recent years as investors and researchers have directed more attention toward conditions that have historically received less funding and scientific focus.
The Startupticker report did not specify which condition or conditions KOVE Medical's device is designed to treat, nor did it detail the timeline for when the First in Human study would begin or how many participants it would involve.
CHF 1.6 million, denominated in Swiss francs, represents a modest seed round by the standards of some medical device companies, but seed-stage funding in medtech is often used specifically to generate the early clinical evidence needed to attract larger investment rounds. Securing even initial human trial data can substantially change a startup's ability to raise follow-on capital.
The company's progress will depend on regulatory clearance to proceed with human testing, a process that varies in timeline depending on the jurisdiction in which the trial is conducted. No regulatory body or trial location was identified in the available reporting.
